KOSSI EKLOU: Open Payments
NPI 1609360635 · MANASSAS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,892 in 64 payments from 10 companies in 2025. Trend: 2023 $514 · 2024 $1,625 · 2025 $1,892
Food & beverage: $1,892
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 18 | $577 |
| Otsuka America Pharmaceutical, Inc. | 7 | $272 |
| E.R. Squibb & Sons, L.L.C. | 9 | $242 |
| Janssen Pharmaceuticals, Inc | 6 | $198 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $191 |
| ABBVIE INC. | 5 | $99 |
| Teva Pharmaceuticals USA, Inc. | 4 | $91 |
| Vanda Pharmaceuticals Inc. | 3 | $85 |
| Neurocrine BioSciences, Inc. | 4 | $82 |
| Lundbeck LLC | 3 | $54 |
Products named: ARISTADA, COBENFY, LYBALVI, INVEGA SUSTENNA, CAPLYTA, ABILIFY ASIMTUFII, REXULTI, VRAYLAR.
Industry payments across VA — which companies pay providers there.
